Api seladelpar supply?

Who owns the seladelpar API?
The active ingredient of seladelpar is owned by AstraZeneca, which holds the exclusive rights to the compound after a 2017 patent filing [7]. The company licenses the drug’s development to Pfizer, but the API remains under AstraZeneca’s control [1].

Where is the API produced?
AstraZeneca outsources the manufacturing of seladelpar’s API to contract‑manufacturing organizations (CMOs). The primary partners are Lonza in Switzerland and Alkem Laboratories in India [4][6]. These facilities handle the complex synthesis of the selective PPAR‑δ agonist, ensuring that the product meets the quality standards required for clinical trials.

How does the supply chain look right now?
Seladelpar is still in the clinical‑trial phase, with phase 3 studies underway for ulcerative colitis. Because of this, the API supply is tightly limited to the clinical trial sites managed by the sponsor [2][3]. No commercial API is available for external buyers, and the quantity produced each month corresponds to the needs of the ongoing trials.

Are there any supply constraints or delays?
Supply constraints arise mainly from the small production scale of early‑phase trials. Manufacturing any drug at such a scale requires meticulous control, and any interruption in raw‑material supply or equipment downtime can delay the entire program. So far, AstraZeneca reports that the supply chain remains stable, but it is not yet clear how quickly the volume could ramp up if the drug gains approval [3].

Who can order the API for research purposes?
Academic or biotech groups can request access to the API through AstraZeneca’s research collaboration programs. The request must go through the company’s regulatory and ethics approvals, and the material is typically provided only under strict confidentiality and safety agreements [3].

What is the regulatory status of the API?
Seladelpar has not yet received FDA or EMA approval. The drug’s API is therefore only licensed for investigational use in the context of the registered clinical trials. No generic or biosimilar version exists because the underlying compound is still proprietary [5].

When could the API reach the market?
If the ongoing phase 3 trials show positive results, AstraZeneca could file for regulatory approval within a year. Commercial API production would then need to scale up, potentially adding new CMO partners. Patents filed in 2017 grant AstraZeneca a 20‑year exclusivity period, so the API should not see generic competition until about 2037 [7].

Are there alternative compounds or biosimilars?